Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
In investigating the role of metal ions in the pathogenesis of Huntington's disease, we examined the effects of clioquinol, a metal-binding compound currently in clinical trials for Alzheimer's disease treatment, on mutant huntingtin-expressing cells. We found that PC12 cells expressing polyglutamine-expanded huntingtin exon 1 accumulated less mutant protein and showed decreased cell death when treated with clioquinol. This effect was polyglutamine-length-specific and did not alter mRNA levels or protein degradation rates. Clioquinol treatment of transgenic Huntington's mice ( R6 / 2 ) improved behavioral and pathologic phenotypes, including decreased huntingtin aggregate accumulation, decreased striatal atrophy, improved rotarod performance, reduction of weight loss, normalization of blood glucose and insulin levels, and extension of lifespan. Our results suggest that clioquinol is a candidate therapy for Huntington's disease and other polyglutamine-expansion diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The iron chelator clioquinol is also protective (Nguyen et al. 2005).”
Citations
Cites
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Analytical profiles of drug substances
(1975) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600640947 · Cited by 1,491
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Gauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Research works printed but not linked: 3
- Perez, P., Flores, A., Santamaria, A., Rios, C. & Galvan-Arzate, S. (1996) Arch. Med. Res. 27, 449-452.8987176
- Maksimovic, I. D., Jovanovic, M. D., Colic, M., Mihajlovic, R., Micic, D., Selakovic, V., Ninkovic, M., Malicevic, Z., Rusic-Stojiljkovic, M. & Jovicic, A. (2001) Vojnosanit Pregl. 58, 237-242.11548547
- Ogata, M., Watanabe, S., Tateishi, J., Kuroda, S. & Otsuki, S. (1973) Lancet 1, 1248-1249.
Cited by
Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis
Bush, A. I., & Tanzi, R. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.001 · Cited by 564
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Metabolism and functions of copper in brain
Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.01.002 · Cited by 506
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497
Microglial Activation in Stroke: Therapeutic Targets
Yenari, M. A., Kauppinen, T. M., & Swanson, R. A. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.005 · Cited by 389
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“The iron chelator clioquinol is also protective (Nguyen et al. 2005).”
BackgroundMetallostasis in Alzheimer's disease
Ayton, S., Lei, P., & Bush, A. I. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.558 · Cited by 352
“impairment of the mice, and extended their lifespan [264].”
BackgroundCopper complexes as therapeutic agents
Duncan, C., & White, A. R. (2012) · Metallomics · doi:10.1039/c2mt00174h · Cited by 294
8-Hydroxyquinolines in medicinal chemistry: A structural perspective
Oliveri, V., & Vecchio, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.007 · Cited by 281
Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein
Bauer, P. O., Goswami, A., Wong, H. K., Okuno, M., Kurosawa, M., Yamada, M., Miyazaki, H., Matsumoto, G., Kino, Y., Nagai, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1608 · Cited by 280
Simmons, D. A., Casale, M., Alcon, B., Pham, N., Narayan, N., & Lynch, G. (2007) · Glia · doi:10.1002/glia.20526 · Cited by 277
“, 2006) and decreased in R6/2 mice administered clioquinol, which chelates iron and other metals (Nguyen et al., 2005), or a low iron diet (Simmons, unpublished results).”
BackgroundElevated cortical zinc in Alzheimer disease
Religa, D., Strozyk, D., Cherny, R. A., Volitakis, I., Haroutunian, V., Winblad, B., Naslund, J., & Bush, A. I. (2006) · Neurology · doi:10.1212/01.wnl.0000223644.08653.b5 · Cited by 276
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases
Chen, L., Shen, Q., Liu, Y., Zhang, Y., Sun, L., Ma, X., Song, N., & Xie, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02071-0 · Cited by 242
Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders
Bareggi, S. R., & Cornelli, U. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00231.x · Cited by 243
“More promising results have been obtained in an in vitro study of huntingtin-expressing cells, which expressed less mutant protein and showed a decreased death rate, and a transgenic mouse model of Huntington’s disease, in which clioquinol improved the behavioral and pathological phenotypes [53].”
ResultThe transition metals copper and iron in neurodegenerative diseases
Rivera-Mancía, S., Pérez-Neri, I., Ríos, C., Tristán-López, L., Rivera-Espinosa, L., & Montes, S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.04.010 · Cited by 244
“CQ reduced polyglutamine expanded levels in vitro and reduced the pathology and behavioural abnormalities of R6/2 transgenic mice, but it is not known if those effects were due to metal chelation or to other mechanisms [246], although it could be suggested that the effect of CQ may involve Cu (II) binding in a 1:2 met…”
BackgroundMyelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications
Bartzokis, G., Lu, P. H., Tishler, T. A., Fong, S. M., Oluwadara, B., Finn, J. P., Huang, D., Bordelon, Y., Mintz, J., & Perlman, S. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9352-7 · Cited by 238
“Early intervention may make it possible to increase effectiveness of treatments, decrease the need for later more aggressive approaches, and ultimately may represent a heretofore unexplored opportunity for primary prevention of degenerative brain diseases [71, 85, 91, 96].”
BackgroundOxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly
Kumar, A., & Ratan, R. R. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160205 · Cited by 236
Mechanisms of Copper Ion Mediated Huntington's Disease Progression
Fox, J. H., Kama, J. A., Lieberman, G., Chopra, R., Dorsey, K., Chopra, V., Volitakis, I., Cherny, R. A., Bush, A. I., & Hersch, S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000334 · Cited by 216
“The brain permeable copper and iron chelator clioquinol is neuroprotective and decreases brain aggregate load in R6/2 HD mice [36].”
BackgroundEffect of Resveratrol on Antioxidant Enzyme Activities in the Brain of Healthy Rat
Mokni, M., Elkahoui, S., Limam, F., Amri, M., & Aouani, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9255-z · Cited by 212
“The copper‐ zinc metal chelator clioquinol prevented MPTP intoxication model of PD [45], beta amyloid accumulation in an AD transgenic mouse model [46] and huntingtin expression in a HD mouse model [ 47 ].”
BackgroundChen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P. V., & Dou, Q. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3546 · Cited by 212
Zhang, L., Huang, Y., Zhou, Y., Buckley, T., & Wang, H. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00670-13 · Cited by 212
“Once the absence of tested AR gene pools was confirmed, mice were subjected to a 4-day inoculation of the bacteria cocktail, during which the 9-strain tet(M)-carrying Enterococcus species cocktail or the 3-strain blaCMY2-carrying Escherichia coli mixture were introduced via gavage feeding (18) using 20-gauge, 1.”
MethodInnocenti, A., Vullo, D., Scozzafava, A., & Supuran, C. T. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.077 · Cited by 198
Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Zhang, Z., Yan, J., Chang, Y., ShiDu Yan, S., & Shi, H. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797200426 · Cited by 189
“Clioquinol-treated transgenic HD mice (R6/2) demonstrate improved behavioral and pathologic phenotypes, including decreased huntingtin aggregate accumulation as well as enhanced motor functions and survival [101].”
Insights into Zn2+ homeostasis in neurons from experimental and modeling studies
Colvin, R. A., Bush, A. I., Volitakis, I., Fontaine, C. P., Thomas, D., Kikuchi, K., & Holmes, W. R. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00541.2007 · Cited by 188
Oxidative stress and neurodegeneration: the involvement of iron
Carocci, A., Catalano, A., Sinicropi, M. S., & Genchi, G. (2018) · BioMetals · doi:10.1007/s10534-018-0126-2 · Cited by 181
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Zinc Triggers Microglial Activation
Kauppinen, T. M., Higashi, Y., Suh, S. W., Escartin, C., Nagasawa, K., & Swanson, R. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1236-08.2008 · Cited by 174
“Treatment with zinc chelators has been shown to reduce neuronal death in animal models of cerebral ischemia, trauma, hypoglycemia, and neurodegenerative disorders (Koh et al., 1996; Suh et al., 2000, 2004; Cherny et al., 2001; Calderone et al., 2004; Nguyen et al., 2005).”
BackgroundInfluentialIron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
Chen, J., Marks, E., Lai, B., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S., & Fox, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077023 · Cited by 174
“HD models [55-57] and thus may in part be targeting our”
BackgroundA Perspective – can copper complexes be developed as a novel class of therapeutics?
Wehbe, M., Leung, A. W. Y., Abrams, M. J., Orvig, C., & Bally, M. B. (2017) · Dalton Transactions · doi:10.1039/c7dt01955f · Cited by 173
Iron dysregulation in movement disorders
Dusek, P., Jankovic, J., & Le, W. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.054 · Cited by 169
Biomedical applications of copper ionophores
Oliveri, V. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213474 · Cited by 169
Alterations in Brain Transition Metals in Huntington Disease: An Evolving and Intricate Story
Rosas, H. D., Chen, Y. I., Doros, G., Salat, D. H., Chen, N.-K., Kwong, K. K., Bush, A., Fox, J., & Hersch, S. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2945 · Cited by 160
“The metal-binding protein clioquinol is neuroprotective in cellular and mouse models of HD, indicating that metal modulation has significant therapeutic potential.(5) However, alterations in iron and copper levels, as well as in other transition metals, during the course of HD remain poorly understood.”
BackgroundHuntington disease arises from a combinatory toxicity of polyglutamine and copper binding
Xiao, G., Fan, Q., Wang, X., & Zhou, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308535110 · Cited by 162
“Clioquinol (CQ), an antibiotic with divalent metal ion-binding ability and whose action mechanism is still controversial (16, 17), improved cell survival and behavioral and pathologic phenotypes in human Htt transgenic mice (18).”
BackgroundThe molecular and cellular basis of copper dysregulation and its relationship with human pathologies
Maung, M. T., Carlson, A., Olea‐Flores, M., Elkhadragy, L., Schachtschneider, K. M., Navarro‐Tito, N., & Padilla‐Benavides, T. (2021) · The FASEB Journal · doi:10.1096/fj.202100273rr · Cited by 175
Simmons, D. A., Belichenko, N. P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S. M., & Longo, F. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1310-13.2013 · Cited by 144
“…the BDNF transgene (Gharami et al., 2008), or various therapeutic approaches (Dedeoglu et al., 2002; Ferrante et al., 2002; Duan et al., 2003; Nguyen et al., 2005; Chopra et al., 2007; DeMarch et al., 2008; Simmons et al., 2011) is associated with improved cognition and/or motor performance…”
BackgroundSelf-citation† (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70262-5 · Cited by 152
Astrocyte functions in the copper homeostasis of the brain
Scheiber, I. F., & Dringen, R. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.017 · Cited by 151
“, 2009), Huntington’s disease (Nguyen et al., 2005; TallaksenGreene et al., 2009) and prion disease (Sigurdsson et al.”
BackgroundGrossi, C., Francese, S., Casini, A., Rosi, M. C., Luccarini, I., Fiorentini, A., Gabbiani, C., Messori, L., Moneti, G., & Casamenti, F. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1063 · Cited by 129
Hypoxia‐inducible factor 1: a new hope to counteract neurodegeneration?
Correia, S. C., & Moreira, P. I. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06443.x · Cited by 144
“Finally, Nguyen et al. (2005) demonstrated the beneficial effects of CQ treatment to reduce cell death and mutant protein accumulation using in vitro models of HD.”
Iron dysregulation in Huntington's disease
Muller, M., & Leavitt, B. R. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12739 · Cited by 124
“It has previously been shown that clioquinol down-regulates mHtt expression in vitro and mitigates pathology in the R6/2 HD mouse model, possibly by silencing redox activity of mHtt (Nguyen et al. 2005).”
BackgroundBulcke, F., Dringen, R., & Scheiber, I. F. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-60189-2_16 · Cited by 137
Mitochondrial iron metabolism and neurodegenerative diseases
Cheng, R., Dhorajia, V. V., Kim, J., & Kim, Y. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.11.003 · Cited by 130
Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases
Whitnall, M., & Richardson, D. R. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.08.008 · Cited by 113
Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
Lee, E.-J., Lee, H., Huang, T.-N., Chung, C., Shin, W., Kim, K., Koh, J.-Y., Hsueh, Y.-P., & Kim, E. (2015) · Nature Communications · doi:10.1038/ncomms8168 · Cited by 110
Iron and Neurodegeneration: Is Ferritinophagy the Link?
Biasiotto, G., Lorenzo, D. D., Archetti, S., & Zanella, I. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9473-y · Cited by 109
Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimer’s Disease
Jain, P., Karthikeyan, C., Moorthy, N. S. H. N., Waiker, D. K., Jain, A. K., & Trivedi, P. (2014) · Current Drug Targets · doi:10.2174/1389450115666140226112321 · Cited by 119
Dunkel, P., Chai, C. L., Sperlágh, B., Huleatt, P. B., & Mátyus, P. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703178 · Cited by 102
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
Wirths, O., Breyhan, H., Schäfer, S., Roth, C., & Bayer, T. A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.004 · Cited by 97
Copper homeostasis and cuproptosis in central nervous system diseases
Zhu, Z., Song, M. S., Ren, J., Liang, L., Mao, G., & Chen, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07206-3 · Cited by 119
“Additionally, TTM and Clioquinol can signi fi cantly delay neuropathological processes in HD mice [115, 116].”
Prati, F., Bergamini, C., Fato, R., Soukup, O., Korabecny, J., Andrisano, V., Bartolini, M., & Bolognesi, M. L. (2016) · ChemMedChem · doi:10.1002/cmdc.201600014 · Cited by 90
Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse
Lei, P., Ayton, S., Appukuttan, A. T., Volitakis, I., Adlard, P. A., Finkelstein, D. I., & Bush, A. I. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.015 · Cited by 93
“in cellular and animal models of PD (11, 21-23), Huntington’s disease (HD) (24), cancer (25-27), and it can protect against aging sequelae (28, 29).”
BackgroundThe curious case of clioquinol
Cahoon, L. (2009) · Nature Medicine · doi:10.1038/nm0409-356 · Cited by 83
Ferrada, E., Arancibia, V., Loeb, B., Norambuena, E., Olea-Azar, C., & Huidobro-Toro, J. P. (2007) · NeuroToxicology · doi:10.1016/j.neuro.2007.02.004 · Cited by 81
“ATP (10 mM) challenges were repeated regularly at 15- min intervals, minimizing receptor desensitization.”
BackgroundMethodInfluentialTardiff, D. F., Tucci, M. L., Caldwell, K. A., Caldwell, G. A., & Lindquist, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308668 · Cited by 79
Cherny, R. A., Ayton, S., Finkelstein, D. I., Bush, A. I., McColl, G., & Massa, S. M. (2012) · Journal of Huntington's Disease · doi:10.3233/jhd-120029 · Cited by 77
Self-citationProfiling donepezil template into multipotent hybrids with antioxidant properties
Mezeiova, E., Spilovska, K., Nepovimova, E., Gorecki, L., Soukup, O., Dolezal, R., Malinak, D., Janockova, J., Jun, D., Kuca, K., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1443326 · Cited by 70
Sumithaa, C., & Ganeshpandian, M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01027 · Cited by 69
Chen, D., & Dou, Q. P. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.739 · Cited by 71
“2 Drugs in hydroxyquinoline family Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline, CQ) ( Figure 2 ), an 8-hydroxyquinoline derivative, is a therapeutic drug for treatment of Alzheimer’s disease [85] and Huntington’s disease [86] .”
BackgroundNiatsetskaya, Z. V., Basso, M., Speer, R. E., McConoughey, S. J., Coppola, G., Ma, T. C., & Ratan, R. R. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2800 · Cited by 81
Shi, L., Huang, C., Luo, Q., Xia, Y., Liu, W., Zeng, W., Cheng, A., Shi, R., & Zhengli, C. (2020) · Aging · doi:10.18632/aging.103225 · Cited by 71
The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease
Gil‐Mohapel, J., & Rego, A. C. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.001 · Cited by 69
“Furthermore, clioquinoltreated 11 week-old R6/2 mice showed normal fasting blood glucose and insulin levels comparable to the ones observed in wild-type controls, indicating that this treatment also ameliorated the diabetic phenotype of these mice (Nguyen et al., 2005).”
ResultRepurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Yang, H., Chen, X., Li, K., Cheaito, H. A., Yang, Q., Wu, G., Liu, J., & Dou, Q. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.013 · Cited by 65
Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo
Charvin, D., Roze, E., Perrin, V., Deyts, C., Betuing, S., Pagès, C., Régulier, E., Luthi-Carter, R., Brouillet, E., Déglon, N., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.028 · Cited by 59
Choi, S., Choi, K.-O., Park, Y.-K., Cho, H.-J., Yang, E. G., & Park, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603913200 · Cited by 67
Tang, B., Becanovic, K., Desplats, P. A., Spencer, B., Hill, A. M., Connolly, C., Masliah, E., Leavitt, B. R., & Thomas, E. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds132 · Cited by 58
Pharmacotherapeutic targets in Alzheimer's disease
Biran, Y., Masters, C. L., Barnham, K. J., Bush, A. I., & Adlard, P. A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00595.x · Cited by 57
Choi, B. Y., Jang, B. G., Kim, J. H., Seo, J.-N., Wu, G., Sohn, M., Chung, T. N., & Suh, S. W. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.01.012 · Cited by 57
The Anti-neurodegeneration Drug Clioquinol Inhibits the Aging-associated Protein CLK-1
Wang, Y., Branicky, R. S., Stepanyan, Z., Carroll, M., Guimond, M.-P., Hihi, A. K., Hayes, S. T., McBride, K., & Hekimi, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807579200 · Cited by 54
Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease
Hands, S. L., Mason, R., Sajjad, M. U., Giorgini, F., & Wyttenbach, A. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380552 · Cited by 54
Bandyopadhyay, S., Huang, X., Cho, H. K., Greig, N. H., Youdim, M. B. H., & Rogers, J. T. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_25 · Cited by 53
“quinol may have therapeutic benefit to reduce huntingtin protein levels as a therapeutic agent for Huntington’s disease (Nguyen et al., 2005).”
BackgroundMRI measures of corpus callosum iron and myelin in early Huntington's disease
Paola, M. D., Phillips, O. R., Sánchez‐Castañeda, C., Pardo, A. D., Maglione, V., Caltagirone, C., Sabatini, U., & Squitieri, F. (2013) · Human Brain Mapping · doi:10.1002/hbm.22391 · Cited by 54
“…make it possible to increase effectiveness of treatment, decrease the need for later more aggressive approaches, and ultimately might represent a heretofore unexplored opportunity for primary prevention of degenerative brain diseases [Bartzokis, 2005; Nguyen et al., 2005; Youdim et al., 2004].”
BackgroundSchäfer, S., Pajonk, F., Multhaup, G., & Bayer, T. A. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0140-7 · Cited by 52
“Recently, interest in CQ has reemerged in the treatment of AD due to its proposed chelating activities observed in an animal study as well as in a phase-II clinical trial [6, 7]. Almost universal applications were suggested based on studies in mouse models of Huntington’s disease [ 17 ], Parkinson’ disease [18], and i…”
BackgroundYang, C., & Yu, R. K. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21817 · Cited by 48
“The Rotarod and Y-maze tests have been previously used to evaluate the motor function and recognition memory, respectively (Carter et al., 1999; Ladurelle et al., 2000; King and Arendash, 2002; Nguyen et al., 2005).”
MethodThe Metal Chelating and Chaperoning Effects of Clioquinol: Insights from Yeast Studies
Li, C., Wang, J., & Zhou, B. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100024 · Cited by 51
“Furthermore, CQ also displayed potential efficacy in the treatment of Parkinson’s disease and Huntington’s disease [29,30].”
Neuroprotection for Huntington’s Disease: Ready, Set, Slow
Hersch, S. M., & Rosas, H. D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.003 · Cited by 54
Neurologic damage in hypoglycemia
Mohseni, S. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00036-9 · Cited by 49
Apolloni, S., Montilli, C., Finocchi, P., & Amadio, S. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06796.x · Cited by 41
Olaleye, O. A., Raghunand, T. R., Bhat, S., Chong, C. R., Gu, P., Zhou, J., Zhang, Y., Bishai, W. R., & Liu, J. O. (2011) · Tuberculosis · doi:10.1016/j.tube.2011.10.012 · Cited by 41
Pan, R., Chen, C., Liu, W., & Liu, K. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12098 · Cited by 39
Derrick, J. S., & Lim, M. H. (2015) · ChemBioChem · doi:10.1002/cbic.201402718 · Cited by 44
Priel, T., Aricha-Tamir, B., & Sekler, I. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.064 · Cited by 38
Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II
Switonski, P. M., Szlachcic, W. J., Gabka, A., Krzyżosiak, W. J., & Figiel, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8316-3 · Cited by 42
Clioquinol Promotes Cancer Cell Toxicity through Tumor Necrosis Factor α Release from Macrophages
Du, T., Filiz, G., Caragounis, A., Crouch, P. J., & White, A. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130377 · Cited by 39
“and inhibited aggregation of huntingtin in a cell model of Huntington’s disease (Nguyen et al., 2005).”
BackgroundMethodNew applications of old metal-binding drugs in the treatment of human cancer
Sara, M. S. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/274 · Cited by 38
“Consequently, CQ is currently in use clinically for the treatment of Alzheimer’s and Huntington’s diseases (132-133).”
BackgroundHarada, A., Suzuki, K., & Kimura, H. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237388 · Cited by 37
“The foot clasping, an abnormal posturing of the hind limb during the tail suspension (Nguyen et al., 2005), is a cardinal phenotype in R6/2 mice (Mangiarini et al., 1996).”
BackgroundAutophagy Mediates Astrocyte Death During Zinc-Potentiated Ischemia–Reperfusion Injury
Pan, R., Timmins, G. S., Liu, W., & Liu, K. J. (2015) · Biological Trace Element Research · doi:10.1007/s12011-015-0287-6 · Cited by 35
Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice
Im, W., Lee, S., Park, J. E., Oh, H. J., Shim, J., Lim, J., Chu, K., & Kim, M. (2010) · PLoS Currents · doi:10.1371/currents.rrn1183 · Cited by 37
Ubiquitin-Proteasome System in Neurodegenerative Disorders
Croft, G. R. B. (2015) · Journal of Drug Metabolism & Toxicology · doi:10.4172/2157-7609.1000187 · Cited by 45
“Clioquinol 20S inhibitor (Cu-mediated interaction) HD [147]”
Therapeutic approaches to preventing cell death in Huntington disease
Kaplan, A. R., & Stockwell, B. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.004 · Cited by 35
Summers, K. L., Roseman, G. P., Sopasis, G. J., Millhauser, G. L., Harris, H. H., Pickering, I. J., & George, G. N. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c02754 · Cited by 35
Screening Candidate Longevity Therapeutics Using Gene-Expression Arrays
Spindler, S. R., & Mote, P. L. (2007) · Gerontology · doi:10.1159/000103924 · Cited by 33
“Thus, these species may be capable of extreme longevity without the downsides associated with CR or dwarfism.Adaptations resulting in extreme longevity might involve either qualitative or quantitative changes in gene expression. Small molecule therapeutics are being developed for genetic diseases caused by alterations…”
BackgroundAntibacterial, spectral and thermal aspects of drug based‐Cu(II) mixed ligand complexes
Kharadi, G. J., & Patel, K. D. (2009) · Applied Organometallic Chemistry · doi:10.1002/aoc.1530 · Cited by 36
Metal attenuating therapies in neurodegenerative disease
Mot, A. I., Wedd, A. G., Sinclair, L., Brown, D. R., Collins, S. J., & Brazier, M. W. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.170 · Cited by 35
Mutant huntingtin induces iron overload via up-regulating IRP1 in Huntington’s disease
Niu, L., Ye, C., Sun, Y. T., Peng, T., Yang, S., Wang, W., & He, L. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0239-x · Cited by 33
Bica, L., Crouch, P. J., Cappai, R., & White, A. R. (2008) · Molecular BioSystems · doi:10.1039/b816577g · Cited by 34
Monitoring Huntington’s Disease Progression Through Preclinical and Early Stages
Tang, C. C., & Feigin, A. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.34 · Cited by 38
“These findings, along with the animal data that clioquinol treatment improved the pathologic and behavioral measures of transgenic Huntington’s mice [76], suggest a novel therapeutic strategy of using metal-binding compounds to normalize brain iron levels and the use of susceptibility-weighted imaging MRI as a potenti…”
ResultWang, J., Chang, Y. K., Zhang, P., Lie, S. Q., Gao, P. F., & Huang, C. Z. (2015) · The Analyst · doi:10.1039/c5an01975c · Cited by 28
Correction: Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
Chen, J., Marks, E. S., Lai, B. C. H., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S. M., & Fox, J. H. (2013) · PLoS ONE · doi:10.1371/annotation/67f555f5-35b7-4468-8bab-26d518942803 · Cited by 30
Metadata
- Authors
- Nguyen, T., Hamby, A., & Massa, S. M.
- Affiliations
- San Francisco VA Medical Center (US)
- ORCID
- Massa, Stephen M.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-08-08
- Volume
- 102
- Issue
- 33
- Pages
- 11840-11845
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1187967
- OpenAlex
- W2009252276
- Cited by
- 194
- References
- 54
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 3 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 13 · 2014: 14 · 2013: 10 · 2012: 14
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- clioquinol, Huntington's disease, mutant huntingtin, polyglutamine expansion, metal ions, huntingtin aggregates, striatal atrophy, R6/2 transgenic mice, neuroprotection, lifespan extension
- MeSH terms
- Huntingtin Protein, Animals, Behavior, Animal, Blood Glucose, Body Weight, Cell Line, Disease Models, Animal, Female, Humans, Huntington Disease, Insulin, Clioquinol, Male, Mice, Transgenic, Mutation, Nerve Tissue Proteins, Nuclear Proteins, Pancreas, Peptides, RNA, Messenger, Down-Regulation, Survival Rate, Cell Death, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.